References
- Acharya S, Sahoo SK. (2011). PLGA NPs containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63:170–183
- Acharya G, Shin CS, Vedantham K, et al. (2010). A study of drug release from homogenous PLGA microstructures. J Control Release 146:201–206
- Aggarwal P, Hall JB, McLeland CB, et al. (2009). NP interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61:428–437
- Beletsi A, Panagi Z, Avgoustakis K. (2005). Biodistribution properties of NPs based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int J Pharm 298:233–241
- Brenner GM, Stevens CW. (2009). Pharmacology. Philadelphia (PA): Saunders Elzevier
- Cartiera MS, Johnson KM, Rajendran V, et al. (2009). The uptake and intracellular fate of PLGA NPs in epithelial cells. Biomaterials 30:2790–2798
- Danhier F, Ansorena E, Silva JM, et al. (2012). PLGA-based NPs: An overview of biomedical applications. J Control Release 161:505–522
- Fredenberg S, Wahlgren M, Reslow M, Axelsson A. (2011). The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems – A review. Int J Pharm 415:34–52
- Gaumet M, Vargas A, Gurny R, Delie F. (2008). Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69:1–9
- Li Y, Pei Y, Zhang X, et al. (2001). PEGylated PLGA NPs as protein carriers: Synthesis, preparation and biodistribution in rats. J Control Release 71:203–211
- Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. (2007). Estradiol loaded PLGA NPs for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 119:77–85
- Mondal N, Halder KK, Kamila MM, et al. (2010). Perparation, characterization, and biodistribution of letrozole loaded PLGA NPs in Ehrlich Ascites tumor bearing mice. Int J Pharm 397:194–200
- Mouse Phenome Database. The Jackson Laboratory. [Online] Available from: http://phenome.jax.org/ [last accessed 4 March 2012]
- Owens DE, Peppas NA. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric NPs. Int J Pharm 307:93–102
- Parveen S, Sahoo SK. (2011). Long circulating chitosan/PEG blended PLGA NP for tumor drug delivery. Eur J Pharmacol 670:372–383
- Phillips MA, Vargas A, Gran ML, Peppas NA. (2010). Targeted nanodelivery of drugs and diagnostics. Nanotoday 5:143–159
- Rat Phenome Database [Online]. Available from: http://www.anim.med.kyoto-u.ac.jp/nbr/strainsx/ow_list.aspx [last accessed 4 March 2012]
- Saxena V, Sadoqi M, Shao J. (2006). Polymeric nanoparticulate delivery system for indocyanine green: Biodistribution in healthy mice. Int J Pharm 308:200–204
- Snehalatha M, Venugopal K, Saha RN, et al. (2008). Etoposide loaded PLGA and PCL NPs II: Biodistribution and pharmacokinetics after radiolabeling with Tc-99m. Drug Deliv 15:277–287
- Tobío M, Sánches A, Vila A, et al. (2000). The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid Surface B 18:315–323
- Tosi G, Vergoni AV, Ruozi B, et al. (2010). Sialic acid and glycopeptides conjugated PLGA NPs for central nervous system targeting: In vivo pharmacological evidence and biodistribution. J Control Release 145:49–57
- Vergoni AV, Tosi G, Tacchi R, et al. (2009). NPs as drug delivery agents specific for CNS: In vivo biodistribution. Nanomedicine 5:369–377
- Yin Y, Chen D, Qiao M, et al. (2007). Lectin-conjugated PLGA NPs loaded with thymopentin: Ex vivo bioadhesion and in vivo biodistribution. J Control Release 123:27–38